Comparison of Relapse Rate After 12 Weeks Verses 20 Weeks Steroid Therapy for the Management of First Episode of Steroid Sensitive Nephrotic Syndrome
NCT04713410 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68
Last updated 2021-05-11
Summary
All children from 1 to 8 years of age, diagnose with nephrotic syndrome for the first time will be divided into two groups. One group will be given steroids for 12 weeks and other group will receive steroid for 20 weeks. During the 1 years after completion of steroid course patients will be monitor for the episodes of relapse in both group.
Conditions
- Steroid-Sensitive Nephrotic Syndrome
Interventions
- DRUG
-
Prednisolone
Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
Sponsors & Collaborators
-
Shaheed Zulfiqar Ali Bhutto Medical University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 1 Year
- Max Age
- 8 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-12-22
- Primary Completion
- 2022-09-04
- Completion
- 2023-09-04
Countries
- Pakistan
Study Locations
More Related Trials
-
Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency
NCT00837863 ·Status: UNKNOWN ·Phase: PHASE2
-
Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children
NCT01237041 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
NCT00102817 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Nutritional Formula Supplementation on Linear Growth of Growth Hormone (GH) Treated Prepubertal Children With Idiopathic Short Stature (ISS) After 2 Years From the Beginning of GH-therapy
NCT04962360 ·Status: RECRUITING ·Phase: NA
-
Treatment of the lOw IGF-1 Syndrome aSsociated With Chronic Heart fAilure: A Randomized, Placebo-Controlled, Double-Blind Study.
NCT01235273 ·Status: SUSPENDED ·Phase: PHASE2
-
Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome
NCT00351221 ·Status: TERMINATED ·Phase: PHASE2
-
Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial
NCT00591760 ·Status: COMPLETED ·Phase: PHASE2
-
Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)
NCT01438801 ·Status: WITHDRAWN ·Phase: PHASE4
-
Growth Retardation In Children With Special Pathological Conditions Or Disease
NCT00163215 ·Status: COMPLETED ·Phase: PHASE3
-
Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome
NCT00705172 ·Status: COMPLETED
-
A Study in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End Stage Renal Disease (ESRD)
NCT00097617 ·Status: COMPLETED
-
Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study
NCT03709381 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study of Zomacton in Children With Growth Hormone Deficiency
NCT00884000 ·Status: COMPLETED ·Phase: PHASE3
-
A Prospective Sub-Study of the Global Hypophosphatasia Registry
NCT05234567 ·Status: RECRUITING
-
A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients
NCT00171613 ·Status: COMPLETED ·Phase: PHASE4
-
Glucocorticoid-induced Osteopenia in Children
NCT00289328 ·Status: COMPLETED
-
A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency
NCT00314938 ·Status: TERMINATED ·Phase: PHASE2
-
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
NCT02616562 ·Status: COMPLETED ·Phase: PHASE2
-
Versartis Trial in Children to Assess Long-Acting Growth Hormone
NCT01718041 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)
NCT00952484 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
NCT05598320 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome
NCT03053271 ·Status: TERMINATED ·Phase: PHASE2
-
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome
NCT02713945 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency
NCT00191165 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
NCT00434148 ·Status: COMPLETED ·Phase: PHASE3